Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Waller

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Pharmacoepidemiology and Drug Safety|March 12, 2011
Getting to grips with the new European Union pharmacovigilance legislationPatrick Waller
Pharmacoepidemiology and Drug Safety|June 19, 2003
Dealing with uncertainty in drug safety: lessons for the future from sertindolePatrick Waller
Lancet (London, England)|June 14, 2011
Mediator: who's to blame?Patrick Waller, Stephen Evans
Drug Safety|January 15, 2004
Is aspirin a cause of Reye's syndrome?Patrick Waller, Rafe Suvarna
Lancet (London, England)|November 11, 2008
Carbocisteine for acute exacerbations of COPDPatrick Waller, Samy Suissa
Drug Safety|July 4, 2013
Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory AgencySuzie Seabroke, Lesley Wise, Patrick Waller
Drug Safety|September 27, 2005
Testing and implementing signal impact analysis in a regulatory setting: results of a pilot studyEmma Heeley, Patrick Waller, Jane Moseley
British Journal of Clinical Pharmacology|January 26, 2006
Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactionsPaul Barrow, Patrick Waller, Lesley Wise
Drug Safety|September 27, 2005
Impact analysis of signals detected from spontaneous adverse drug reaction reporting dataPatrick Waller, Emma Heeley, Jane Moseley
Pharmacoepidemiology and Drug Safety|August 19, 2004
The reporting odds ratio versus the proportional reporting ratio: 'deuce'Patrick Waller, Eugène van Puijenbroek, Antoine Egberts, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmacoepidemiology and Drug Safety|March 12, 2011
Getting to grips with the new European Union pharmacovigilance legislationPatrick Waller
Pharmacoepidemiology and Drug Safety|June 19, 2003
Dealing with uncertainty in drug safety: lessons for the future from sertindolePatrick Waller
Lancet (London, England)|June 14, 2011
Mediator: who's to blame?Patrick Waller, Stephen Evans
Drug Safety|January 15, 2004
Is aspirin a cause of Reye's syndrome?Patrick Waller, Rafe Suvarna
Lancet (London, England)|November 11, 2008
Carbocisteine for acute exacerbations of COPDPatrick Waller, Samy Suissa
Drug Safety|July 4, 2013
Development of a novel regulatory pharmacovigilance prioritisation system: an evaluation of its performance at the UK Medicines and Healthcare products Regulatory AgencySuzie Seabroke, Lesley Wise, Patrick Waller
Drug Safety|September 27, 2005
Testing and implementing signal impact analysis in a regulatory setting: results of a pilot studyEmma Heeley, Patrick Waller, Jane Moseley
British Journal of Clinical Pharmacology|January 26, 2006
Comparison of hospital episodes with 'drug-induced' disorders and spontaneously reported adverse drug reactionsPaul Barrow, Patrick Waller, Lesley Wise
Drug Safety|September 27, 2005
Impact analysis of signals detected from spontaneous adverse drug reaction reporting dataPatrick Waller, Emma Heeley, Jane Moseley
Pharmacoepidemiology and Drug Safety|August 19, 2004
The reporting odds ratio versus the proportional reporting ratio: 'deuce'Patrick Waller, Eugène van Puijenbroek, Antoine Egberts, et al.
Pageof 2